

# Table of Contents

## Section I: Quality Management Systems

Chapter 1	Setting up a Quality Management System .....	1
	By Abhishek Harde, PMP, RAC	
Chapter 2	Medical Device Quality Management Systems .....	35
	By Gert Bos, MSc, PhD, FRAPS	
Chapter 3	Canadian Medical Device Quality System Requirements .....	47
	By Karen Fan, MSc, RAC, Peng, Charles Tam, MBA, and Danuta Zylka	
Chapter 4	Quality Systems and Inspectorate Process for Pharmaceuticals .....	63
	By Siegfried Schmitt, PhD	
Chapter 5	Regulatory Requirements for Design and Process Validation .....	85
	By Robert V. Packard and Leo Lagrotte	
Chapter 6	Quality Risk Management—A Gateway to Quality by Design.....	93
	By Peter Schiemann, PhD and Beat Widler, PhD	
Chapter 7	Product Lifecycle Management Guidance .....	105
	By Ajay Babu Pazhayattil, Naheed Sayeed-Desta, and Queenia Lee	

## Section II: Laboratory Testing

Chapter 8	Good Laboratory Practice for Nonclinical Laboratory Studies.....	113
	By Navneet Sekhon	
Chapter 9	Nonclinical Laboratory Testing.....	121
	By Dorota Grabowska, PhD and Peter A. Takes, PhD, RAC, FRAPS	
Chapter 10	Medical Device Preclinical Testing .....	135
	By Jan-Paul van Loon, MSc, PhD and Gert Bos, MSc, PhD, FRAPS	

Chapter 11	Preclinical Testing and Good Laboratory Practice Regulations .....	145
	By Anu Gaur, PhD, MBA, MSRA, RAC	

Chapter 12	Good Laboratory Practice Regulations .....	155
	By Kurt Stahl and Jennifer G. Brown, PhD, RAC	

### **Section III: Production**

Chapter 13	Manufacturing .....	169
	By Andrea Armando, RAC	

Chapter 14	Current Good Manufacturing Practices and Quality System Design .....	177
	By Joscelyn Bowersock, MS-RA and Richard Vincins, CQP, MCQL, CBA, CQA, RAC	

Chapter 15	Canadian Good Manufacturing Practices and Establishment Licensing .....	197
	By Bocar Guisse, MSc and Fraidiane Sévigné	

Chapter 16	Impact of Good Manufacturing Practices on Printed Packaging Components .....	215
	By Debra Goetchius	

Chapter 17	CMC Regulatory Strategy .....	237
	By Stephen Antonelli and Michael Craig	

Chapter 18	Fundamental Principles for Labeling and Promotion of Prescription Medical Products .....	247
	By Joanne S. Hawana, MS, JD, Bethany J. Hills, MPH, JD, and Benjamin M. Zegarelli, MS, JD	

### **Section IV: Clinical Studies**

Chapter 19	Clinical Trials, Good Clinical Practice, Regulations, and Compliance .....	295
	By Anu Gaur, PhD, MBA, MSRA, RAC, Bettina Merz-Nideroest, MPharm, and Andrea Zobel, PhD	

Chapter 20	Canadian Clinical Trial Applications, Good Clinical Practices .....	313
	By Mahdis Dorkalam, MSc, RHN, and Navneet Sekhon	

Chapter 21	EU Clinical Evaluation and Clinical Investigations .....	325
	By Loes Pelgrim, MSc and Gert Bos, MSc, PhD, FRAPS	

Chapter 22	Clinical Trials: GCPs, Regulations and Compliance for Drugs, Biologics and Medical Devices .....	333
	By Monique Carter, MS, RAC and Samantha Zappia, MS, RAC	

## Section V: Inspection, Compliance, and Enforcement

Chapter 23	Compliance and Enforcement .....	377
	By David W. Husman, PhD, ASQ CPGP, RAC and John Rossman, MBEE, RAC	
Chapter 24	FDA Inspection and Enforcement.....	399
	By Robert Rogers, MS, RAC	
Chapter 25	Components of a REMS: Communication Plans and Implementation Systems.....	411
	By Edward Tabor, MD	
Chapter 26	Components of a REMS: Elements to Assure Safe Use.....	413
	By Edward Tabor, MD	
Chapter 27	Components of a REMS: REMS Assessment.....	419
	By Edward Tabor, MD	
Chapter 28	Risk Management in the Medical Device and Food Industries .....	423
	By Salma Michor, PhD, MBA, CMgr, CQA, RAC	

### Tables

Table 1-1. Key Differences Between ISO 9001 and ISO 13485 .....	1
Table 1-2. Similarities Between ISO 9001 and ISO 13485.....	2
Table 1-3. Comparison of ISO 13485:2003 and ISO 13485:2016.....	6
Table 1-4. Applicability of ISO 13485 in Various Global Jurisdictions.....	12
Table 1-5. Benefits and Barriers to Certification.....	20
Table 1-6. Certification Body QMS Assessment Objectives, Scope and Criteria .....	20
Table 1-7. Audit Duration for Medical Device ISO 13485 Audits Based on Staff Numbers .....	22
Table 1-8. Factors That May Increase or Reduce Audit Durations .....	22
Table 4-1. PIC/S Member States.....	78
Table 6-1. Traditional Quality Management vs. QRM Approach.....	101
Table 9-1. The Universal Elements of GLP.....	123
Table 9-2. Examples of GLP Violations From FDA Warning Letters .....	124
Table 9-3. Sources of Device Risk .....	125
Table 9-4. Biocompatibility Tests .....	125
Table 9-5. Medical Device Classification Based on the Nature of Body Contact and Contact Duration .....	126
Table 9-6. Basic Animal Study Protocol Elements.....	127
Table 9-7. Animal Models for In Vivo Medical Device Assessment.....	129
Table 9-8. International Animal Research Laws, Policies and Guidelines .....	129
Table 9-9. Useful Web Resources for Planning and Conducting Animal Studies in Accordance With the Three Rs' Principles .....	130
Table 9-10. Questions a Company Should Consider When Selecting a CRO .....	132
Table 16-1. Select Resources on Pictogram Use.....	222
Table 17-1. Centralised Procedure Requirements Based on Product Type.....	239
Table 17-2. Regulatory Authorities by Country .....	239

Table 18-1. Selected FDA Regulations for the Labeling of Prescription Drugs .....	248
Table 18-2. Selected FDA Regulations for Device Labeling.....	249
Table 18-3. FDA's Categorization of Promotional Materials (21 CFR 202.1(l)) .....	250
Table 18-4. Summary of PI Sections Under the PLR, Including Relevant Regulations and Available Guidance .....	257
Table 18-5. Other Product Claim Types .....	266
Table 18-6. Risk-Related Sections of the PI Ranked From Most to Least Important.....	271
Table 19-1. Regional Regulatory Authorities .....	302
Table 19-2. Trial Master File Essential Documents .....	310
Table 20-1. Contents of a CTA Submission Package.....	317
Table 20-2. Quality Changes-Biologics and Radiopharmaceuticals.....	318
Table 20-3. Quality Changes—Pharmaceuticals.....	319
Table 20-4. Postapproval Requirements .....	322
Table 22-1. Significant Legislation Relevant to Clinical Trials in the US .....	335
Table 22-2. Comparison of 21 CFR and ISO-GCP Requirements for Protocol Deviations in Medical Device Clinical Trials..	341
Table 22-3. Comparison of 21 CFR and ISO GCP Requirements for Investigator Responsibilities in Medical Device Clinical Trials..	367
Table 22-4. Comparison of 21 CFR and ISO-GCP Requirements for Recordkeeping in Medical Device Clinical Trials .....	370
Table 22-5. Comparison of 21 CFR and ISO-GCP Requirements for Device Accountability in Medical Device Clinical Trials ...	370
Table 23-1. Applicability of GxPs to Standardized Market Authorization Application Formats .....	388
Table 24-1. FDA Enforcement Actions .....	405
Table 26-1. ETASUs Approved Per Year .....	414
Table 28-1. Content Deviations Between ISO 14971:2007 and Directive 93/42/EEC on Medical Devices .....	424

## Figures

Figure 1-1. Basic Process Model .....	3
Figure 1-2. PDCA Cycle in Resource Management.....	4
Figure 1-3. Mandatory Procedures and Documents for ISO 13485:2003.....	11
Figure 1-4. Implementing an ISO 13485:2016 QMS.....	13
Figure 1-5. Sample Schedule for QMS Implementation .....	15
Figure 1-6. QMS Documentation Defining Responsibilities.....	16
Figure 1-7. Typical QMS Document Hierarchy .....	17
Figure 1-8. Iterative PDCA Cycle .....	20
Figure 1-9. ISO 17021 QMS Certification Cycle.....	21
Figure 1-10. Design Process .....	27
Figure 2-1. Process Flow of Interrelated QMS Processes .....	36
Figure 2-2. PDCA Methodology.....	37
Figure 2-3. Requirements Clauses in ISO 13485:2016.....	38
Figure 2-4. Design and Development Control Steps .....	40
Figure 2-5. Influence of Design Controls on the Design Process.....	40
Figure 2-6. Process Validation Decision Tree .....	43
Figure 2-7. Key Activities for Supplier Control .....	45
Figure 3-1. MDSAP Audit Sequence .....	55
Figure 3-2. MDSAP Nonconformity Grading Overview .....	57
Figure 3-3. MDSAP Nonconformity Grading Matrix .....	58
Figure 3-4. MDSAP Post-Audit Activities and Timeline.....	59
Figure 4-1. Drug Lifecycle Regulations .....	63
Figure 4-2. Assessors and Inspectors.....	64

Figure 4-3. EU Legal Instruments .....	67
Figure 4-4. Inspections as Part of the Drug Approval Process .....	68
Figure 6-1. Failure Mode and Effect Analysis Cycle.....	96
Figure 6-2. Three-step RPN-based Risk Evaluation .....	99
Figure 6-3. Example of QRM in Action .....	100
Figure 9-1. Strategy for Performing Animal Studies.....	128
Figure 16-1. NDC Number Example .....	218
Figure 16-2. Trade Bottle Label .....	225
Figure 16-3. Small Container Label (Small Label Exemption Rule).....	225
Figure 16-4. Folding Carton for Pharmaceutical Drug Product .....	228
Figure 16-5. Biologic Label.....	231
Figure 16-6. Biologic Carton Label.....	231
Figure 19-1. Acceptance of Foreign Clinical Data .....	301
Figure 19-2. Quality Management System .....	306
Figure 22-1. Types of Pharmaceutical and Biologic Clinical Trials and Typical Pathway .....	342
Figure 22-2. Types of Medical Device Clinical Trials and Typical Pathway.....	361
Figure 23-1. TPLC Cycle for Devices.....	379
Figure 23-2. Medical Device Design Control and Review Process .....	380
Figure 28-1. The Risk Management Process .....	425
Figure 28-2. Principal Activities for Risk Management .....	427
Figure 28-3. The Risk Management Process .....	430

**Sidebars**

Sidebar 18-1. Enforcement Example Mirapex 9/2008 .....	251
Sidebar 18-2. Enforcement Example Focalin XR 5/2011 .....	265
Sidebar 18-3. Enforcement Example Idelvion, 2/2018.....	269
Sidebar 18-4. Enforcement Example Estring 6/2018 .....	270
Sidebar 18-5. Enforcement Example Vantas 9/2012.....	273
Sidebar 18-6. Enforcement Example Contrave 5/2017.....	276
Sidebar 18-7. Enforcement Example Muse 5/2004 and 4/1998 .....	277
Sidebar 18-8. Enforcement Examples MiraLax 3/2001 and Patanol 3/2001 .....	279
Sidebar 18-9. Enforcement Example Tasigna 7/2010 .....	284
Sidebar 18-10. Enforcement Example NCS Pearson 8/2015 .....	289